Skip to main content
Northwestern University Feinberg School of Medicine
Department of Urology
Skip to main content

Urologic Cancers

Researching mechanisms of bladder and kidney cancer initiation and progression to develop novel therapeutics and treatments for genitourinary malignancies.

 Shilajit Kundu Lab

Prospectively studying quality of life outcomes in patients with urologic cancers

Research Description

Dr. Kundu has successfully conducted and published on prospective evaluations of patients with urologic cancers and found that the impact of cancer treatment goes beyond physical limitations associated with treatment. The application of these findings have resulted in interventions to improve the physician-patient relationship, patient education and the health care environment overall.

Dr. Kundu is currently performing genetic studies to distinguish mechanisms that drive prostate cancer development in men with inflammatory bowel disease (IBD). His research aims to identify the specific factors underlying prostate cancer and IBD to uncover the mechanisms that may drive carcinogenesis in this inflammatory condition.

Select Publications

 Joshua Meeks Lab

Investigating genetic and epigenetic changes in bladder cancer, as well as immuno-oncology in bladder cancer

Research Description

The Meeks lab is investigating the epigenetics and genetic mutations associated with cancer biology. Specifically, he is studying how chromatin remodeling genes play a role in bladder cancer. In addition, he is investigating the “driver mutations found in bladder cancer. In the future, he hopes to develop novel systemic and intravesical therapies to improve survival of patients with bladder cancer.

Select Publications

Refer to PubMed for a full list of publications. 

Email Dr Meeks

Phone 312-695-8146

 C. Shad Thaxton Lab

Fabricating new nanomaterials and translational nanotechnology with regard to nanoparticle-based molecular diagnostics and nanotherapeutics.

Research Description

Shad Thaxton MD, PhD, invented, synthesized, and characterized the first biomimetic high-density lipoprotein nanoparticles. High density lipoproteins (HDLs) are natural nanoparticles that circulate in the human body to carry cholesterol. Cholesterol carried by HDLs is often referred to as “good cholesterol” because HDL blood levels inversely correlate with the development of cardiovascular disease. The Thaxton Group utilizes a gold nanoparticle scaffold to assemble the natural surface chemical components of HDLs to create synthetic HDL nanoparticles. The HDL nanoparticles recapitulate the size, shape, surface chemistry, and cholesterol binding properties of natural HDLs. As such, The Thaxton Lab is using these unique biomimetic materials to better understand the structure-function properties of natural HDLs and also as potential therapies for atherosclerosis and heart disease.

For more information, see the faculty profile of  C. Shad Thaxton, MD, PhD

Publications

View Dr. Thaxton's other publications at PubMed

Contact

Email Dr. Thaxton

Phone 312-503-1826

Lab Staff

Post-doctoral Fellows

Nick Angeloni, Kannan Mutharasan, Jonathan Rink

Graduate Students

Kaylin M. McMahon, Michael Plebanek, Sushant Tripathy, Andrea Luthi

Research Technician

Amritha Singh

 Jennifer Wu Lab

Understanding the mechanisms of cancer immune evasion and development of novel immune therapy

Research Description

Dr. Wu's research focuses on understanding the very fundamental questions of cancer development and progression with the ultimate goal to translate our knowledge into clinics. Dr. Wu’s laboratory is interested in specific aspects of Onco-immune interaction and cancer biology:

  1. Mechanisms of cancer immune evasion and development of novel cancer immunotherapy with specific focus on the NKG2D signaling pathways
  2. Inflammation and cancer with focus on understanding the role of the proinflammatory cytokine IL-6 in cancer initiation and progression
  3. Cancer biomarker discovery with focus on identifying biomarkers to distinguish progressive vs. indolent prostate cancer and to biomarkers to predict cancer patients at large who will be the better responders to immune checkpoint therapy

For more information please view the faculty profile of Jennifer Wu, PhD.

Recent Publications

View a full list of publications by Jennifer Wu at PubMed

Contact Us

Email Jennifer Wu, or phone at 312-503-1521

Back to top

Follow Urology on